55 results about "Retina/choroid" patented technology

Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region.

Featured is a methodology for administering a therapeutic medium to the posterior segment of an eye including instilling or disposing the therapeutic medium sub-retinally. In particular embodiments, the therapeutic medium is disposed in a sub retinal space. Such instillation being accomplished by one of injection or implantation of the therapeutic medium sub-retinally or the sub-retinal space. In other aspects, the methodology further includes forming a limited retinal detachment so as to define the sub-retinal space as well as methods for treating an eye by sub-retinally administering a therapeutic medium.

The invention provides methods for delivering a therapeutic or diagnostic agent to the eye of a mammal. The method involves contacting sclera with a therapeutic or diagnostic agent so as to permit its passage through the sclera into the choroidal and retinal tissues. The sclera may be contacted with a therapeutic or diagnostic agent together with a device for enhancing transport of the agent through the sclera.

The invention discloses a choroid layer automatic partitioning method based on a high-definition frequency domain optical coherence tomography (HD-OCT) image, and belongs to the technical field of image processing. According to the method, input HD-OCT images are subjected to denoising preprocessing first, a high-reflectance zone near a retina nerve fiber layer is removed by locating an internal limiting membrane, then the lower boundary of a retinochrome epithelial layer, namely the upper boundary of a choroid layer is located through high-reflectance information, finally candidate CSI boundary points obtained through the image features of the lower boundary of the choroid layer are connected through a graph searching method, and the CSI boundary of choroid membranes is obtained. Test results show that choroid layer partitioning accuracy is high and is equal to that of manual partitioning results, the method can replace the complex time-consuming work that a clinician measures the thickness of the choroid membranes manually, and significance in improving of working efficiency of a doctor is achieved.

The invention relates to sustained release implants and to methods for treating eyes, particularly the eyes of mammals having eye disorders or diseases. By using the implants and methods described herein, the delivery of the one or more bioactive agents can be localized at a desired treatment site, particularly the choroid and the retina.

The invention discloses an OCT image choroid segmentation method based on an improved U-net network. The main improvement points of the U-net include: (1) extracting more by increasing the number of encoders and decoders in the network. Feature information; (2) Adding an exquisite residual block after the encoder to enhance each layer's recognition capability; (3) Adding a attention module behindthe decoder to let the high-level semantic information guide the underlying details; (4) Using the loss function The traditional L2 loss and Dice loss are combined to constrain the network model. Theimproved U-net network of the present invention can automatically segment the upper and lower boundaries of the choroid of the human eye or the pathological myopia, and the segmentation result is highly accurate.

The invention is a retinal implant device to stimulate a retina of an eye thereby producing a specific effect in an eye, such as vision or drug treatment of a chronic condition. The retinal device is made of a retinal implant that is positioned subretinally and that contains a multitude of stimulation sites that are in contact with the retina. A connection carries the stimulating electrical signal or drug. The connection passes transretinally through the retina and into the vitreous cavity of the eye, thereby minimizing damage to the nutrient-rich choroid. The lead is attached to a source of drugs or electrical energy, which is located outside the eye. The lead passes through the sclera at a point near the front of the eye to avoid damage to the retina.

Age-related macular degeneration is treated by radiation delivered from a miniature x-ray tube inserted via a catheter around the globe of the eye, to a position behind the macula. Methods are described for properly locating the catheter and x-ray tube, using illumination on the catheter and viewing through the front of the eye, or sensors on the catheter and a scanned beam shone from the front of the eye. Fluorescent material excited by x-rays can also be used. Also described are methods and devices for immobilizing the probe once properly located in the eye, for standoff of the x-ray tube from the target issue, and for achieving prescription radiation dose in the choroid while eliminating dose to adjacent tissues. The x-ray treatment can be enhanced using a radiosensitizing drug, and can be combined with PDT.

Formulations and methods useful to reduce ocular neovascularization (new blood vessels in the cornea, retina, conjunctiva, and / or choroid) are disclosed. According to the invention the formulation will include tetracycline or a derivative thereof including chemically modified tetracyclines (CMT) which inhibit matrix metalloproteinase (MMP) activity at a substantially neutral pH in a pharmaceutically acceptable form suitable for delivery to the eye in an amount and for a duration sufficient to reduce ocular neovascularization. According to the invention the formulations are preferably in pharmaceutically acceptable formulations for topical ocular application, ocular injection, or ocular implantation, and may be contained in liposomes or slow release capsules.

A visual restoration aiding device for restoring vision of a patient, comprises: a substrate which will be placed on or under a retina, a choroid or a sclera of a patient's eye; a plurality of electrodes arranged on the substrate for applying electrical stimulation pulse signals to cells constituting the retina; a photographing unit which photographs an object to be recognized by the patient; and a control unit which controls output of the electrical stimulation pulse signals from each electrode based image data captured by the photographing unit. The number of the electrodes placed on the substrate is less than the number of electrodes that can simultaneously output the electrical stimulation pulse signals based on the image data corresponding to one frame. The control unit is configured to sequentially output the electrical stimulation pulse signals at predetermined time interval based on the divided image data corresponding to one frame so as to allow the patient to recognize the image corresponding to one frame by joining two or more divided sections of the image corresponding to one frame.

Discussed is a method and apparatus of correcting retinal detachments by heat-shrinking a specially designed scleral band equipped with a snap-on custom-made buckle for scleral indentation over the retinal tear region. The heat shrink band is made from a heat shrink material such as a polymer or an alloy and is equipped with a custom-made buckle to perfectly fit the topological geometry of the retinal detachment region over the underlying choroid and the sclera, the conjunctiva and within the Tenon's space wherein the band is heat shrunk to create a perfect buckle over the retinal tear region to reattach the retina to the choroid and cause absorption of the subretinal fluid. Conventional, laser, microwave, Joule or radio-frequency (RF) heating means are also discussed.

Formulations and methods useful to treat ocular neovascularization (new blood vessel growth in the cornea, retina, conjunctiva, and / or choroid) are illustrated. According to the invention there is provided a formulation suitable for the treatment of ocular neovascularization that may comprise heparin in a concentration and dose suitable for treating ocular neovascularization, characterized in that said compound is at a substantially neutral pH in a pharmaceutically acceptable form suitable for delivery to the eye. Use of drugs like steroids in the treatment of such ocular neovascularization ailments can increase intraocular pressure (glaucoma).

Although a lamina cribrosa is deformed in glaucoma, in a method in a related art, a thickness of retinal layer or choroid is measured and a deformation of the lamina cribrosa is not detected. When glaucoma is diagnosed, it is desirable to analyze a shape of the lamina cribrosa and present its analysis result at a high visibility. An image processing apparatus is provided that comprises: an image obtaining unit that obtains a tomographic image of a subject's eye; an extracting unit that extracts a lamina cribrosa from the tomographic image; and a display control unit that controls a display means to display a display form showing a shape of the extracted lamina cribrosa.

The invention discloses a frequency domain OCT based whole-eye imaging and parameter measuring method and system. The whole-eye imaging and parameter measuring system includes a ranging system and a target system; through the conversion of anterior segment-posterior segment measurement, a lens can move to change the distances to the front of the eyes; and the measuring system can measure the boundary distance of each segment in anterior segments and posterior segments, and includes the measurement calculating on ocular axial lengths and anterior and posterior mean cornea and the identificationcalculating on central corneal thicknesses, lens thicknesses, anterior chamber depths and total thicknesses of the anterior segments even on the thicknesses of retina and choroid. Compared with traditional instruments which can only perform imaging on the anterior segments or the posterior segments, the system can combine the imaging of the anterior segments and the posterior segments at a lowercost, so that the imaging and parameter measuring of whole eyes can be realized, and therefore, the measuring system and method have great advantages on the investigation of ophthalmic diseases and the location of eye diseases.

An object of the present invention is to find a novel medicinal use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof. 2-Phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof exhibits an excellent inhibitory effect on neovascularization in the choroid and also has a protective effect on retinal pigment epithelial cell damage, and therefore is useful as a prophylactic or therapeutic agent for age-related macular degeneration.

The invention discloses a retina stratification method in an eye ground OCT (Optical Coherence Tomography) image. The eye ground OCT image is acquired as an original image; the integral original imageis traversed by using a weight coefficient matrix template to carry out template filtering; and then RPE (Retina Pigment Epithelium) / Choroid gray scale stratification, ILM (Internal Limiting Membrane) layer identification, IS / OS (Inner Segment / Outer Segment) gradient search, NFC / GCL (Nerve Fiber Layer / Ganglion Cell Layer) feature extraction, OPL / ONL (Outer Molecular Layer / Outer Nuclear Layer) energy function optimization and INL (Inner Nuclear Layer) / OPL and IPL (Inner Molecular Layer) / INL path search are carried out, and finally, segmentation on different layers of the retina in the OCT image is completed. The retina stratification method in the eye ground OCT image, which is disclosed by the invention, can implement automatic segmentation on multiple layer structures by utilizing a computer which is commonly configured, implements effective automatic detection on a complex disease stratified structure of the retina, adopts serialized stratification, has few original processing stepsfor the image, and has a certain advantage in detection efficiency.

Formulations and methods useful to treat ocular neovascularization (new blood vessel growth in the cornea, retina, conjunctiva, and / or choroid) are disclosed. According to the invention there is provided a formulation suitable for the treatment of ocular neovascularization that may comprise flurbiprofen in a concentration and dose suitable for treating ocular neovascularization, characterized in that said flurbiprofen may be at a substantially neutral pH in a pharmaceutically acceptable form suitable for delivery to the eye.

The invention provides an application of puerarin gel eye drop in preparation of drugs for treating ischemic ocular fundus diseases. The eye drop is prepared from puerarin, EDTA, sodium metabisulfite, borneol, benzalkonium bromide, poloxamer 407, sodium hyaluronate, sodium citrate, citric acid and injection water, an HPLC-UV method is adopted, intraocular pharmacokinetics of rabbits proves that the absorbed doses of 1.2% puerarin gel eye drop in retina and choroid are respectively larger than 70% and 62% in common puerarin eye drop; converted according to specific gravity of aqueous fluid and vitreous body, intraocular puerarin contents satisfy the relation that choroid> retina>aqueous fluid > vitreous body, which indicates that an enough absorbed dose of the puerarin can reach ocular fundus. Observation finds that average drug contents (ng / g) of the 1.2% puerarin gel eye drop on time points of a 1-6 hour puerarin time-concentration curve of rabbit retina and choroid are not lower than contents (ng / g) measured when rabbits effectively induce reinforced ocular fundus blood flow velocity in retina hemodynamics measurement, so that the fact that the puerarin gel eye drop can be used as intravenous puerarin for treating ischemic ocular fundus diseases can be proved.

The present inventors administered a peptide derived from VEGFR-2, which is known as one of the proteins involved in neovascularization, to model mice (A2 / Kb transgenic mice) expressing human HLA-A*0201, and tested whether or not the peptide has vaccine effect. As a result, the present inventors successfully discovered that vaccination using this peptide as an antigen is effective for inhibition of choroid neovascularization, and thereby completed the present invention. More specifically, the present invention provides vaccines for treatment and / or prevention of diseases caused by choroid neovascularization (neovascular maculopathy), which contain a VEGFR-2-derived peptide as an active ingredient.

The present invention provides novel pharmaceutical agents and methods for treating or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy). The present invention provides pharmaceutical compositions and vaccines for treating and / or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy), comprising at least one type each of a peptide comprising an amino acid sequence derived from a VEGFR-1 protein and having an activity of inducing cytotoxic T cells, and a peptide comprising an amino acid sequence derived from a VEGFR-2 protein and having an activity of inducing cytotoxic T cells.

The invention discloses a method for measuring the diameter of the maximum choroid blood vessel based on image segmentation. The method comprises the following steps: firstly performing image pre-processing on a choroid in a SD-OCT retina image, then adopting the method of image segmentation to extract a region of interest and performing related calculation on the region, and finally outputting a measuring result. According to the invention, the method reduces measuring errors by making the obtained diameter of the choroid maximum blood vessel with an improved precision than the diameter obtained by manual measuring. The method, by using the simple and rapid image segmentation technology, increases accuracy and efficiency in measuring the diameter of the choroid blood vessel, and has great significance in facilitating successive choroid diseases analysis and improving doctor's working efficiency.

The invention discloses a choroid and iris stitching instrument which comprises a rod-shaped handle and a stitching needle fixedly connected with the handle. The stitching needle is in the shape of a solid round rod; the length of the stitching needle is 30-40 mm; the diameter of the stitching needle is 0.5-0.6 mm; and a thread hole is formed in the tip of the stitching instrument. The choroid and iris stitching instrument is simple in structure, quick and easy to operate and suitable for stitching various traumatic choroids and irises. Incisions are small, the needle can enter an eye to stitch under a microscope, and stitching accuracy is guaranteed; in addition, operation steps can be reduced obviously, and operation time is shortened; injury on other tissues is reduced; and technical requirements on doctors are reduced relatively. In a word, a powerful technical support is provided for stitching of choroids and irises, and the choroid and iris stitching instrument has a quite important clinical practical significance.

The invention discloses a choroidal neovascularization growth protection method combining a constitutive model with a finite element. The method comprises the steps of image preprocessing; area division and partition, specifically including dividing an image into four areas consisting of a CNV area, an outer retina layer, an inner retina layer and a choroids layer; meshing, specifically including performing tetrahedral mesh generation on the four areas; modeling, specifically including modeling by using a hyperelastic biomechanical model and a reaction diffusion equation, and adding quality variation after choroidal neovascularization grows into an equation as a source item, thus causing a deformation gradient tensor to continuously change according to the growth of the new vessel; optimizing the model, computing the best accuracy rate, and performing parameter test; and fitting a parameter curve according to a parameter predicted at each time point, and predicting the growth parameter of the last time point to acquire a prediction result. According to the method provided by the invention, the biomechanical model can be built in a more flexible and personalized mode, the model assumes that organization is orthotropic, the good prediction results can be provided for non-linear large-deformation areas, and the accuracy is high.

Disclosed are devices, systems and methods for non-invasive neuromodulation system for treating inherited or acquired retinal, choroidal and optic nerve disorders caused by acute or chronic dysregulated reduced ocular blood flow (OBF) and / or energy failure by up regulation of trigemino-vascular system (TVS), trigeminal autonomic brain reflexes (TABRs) and pancreatic trigemino-vagal reflex (TVR) through stimulation of ophthalmic nerve (V1), more specifically but not limited to SP, and CGRP containing unmyelinated C nerve fibers. The invention, in some embodiments thereof, relates to the methods for enhancing SP and CGRP expression in neurovascular tissue of the retina and choroid. The invention, in some embodiments thereof, relates to SP / CGRP mediated pathways, including those involved in vasodilatation, augmentation of OBF, RPE proliferation, prevention of apoptosis, suppressing neuroinflammation, promoting migration and differentiation of vascular endothelial cells as well as mobilization of endogenous mesenchymal stem cells (EMSCs) from the bone marrow to the circulation to accelerate tissue repair. The site of stimulation of V1 nerve includes but not limited to; nasal vestibule nasal bridge, forehead, and upper eyelids. Additionally or alternatively, the subject's sympathetic nervous system (SNS) is down regulated by sympatholytic agents specifically antioxidants. The subject's TVS and autonomic nervous system (ANS) are modulated in a manner that is effective to treat the subject for retinal, choroidal and / or optic nerve disorders. In some embodiments, the devices are handheld, portable with nose supported, having one or more intra-nasal or extra-nasal application heads. The signal can include vibration, chemical, ultrasonic, optical, electrical, hybrid electro-optical or combination of two or more of these types of stimuli. The invention, in some embodiments thereof, relates to a method for decreasing vascular resistance, enhancing vasodilatation in ophthalmic artery and its branches by the release of Vasoactive intestinal peptide (VIP),substance P and CGRP thereof increasing OBF to the retina, choroid and optic nerve in subject's with acute or chronic dysregulated, reduced OBF. The invention, in some embodiments thereof, is also related to the methods for improving delivery of oxygen, glucose, vitamin A, humoral mediators, growth factors, stem cells and pharmacological agents to the targeted tissues of the retina, choroid and optic nerve. The invention, in some embodiments thereof, relates to the methods for improving pancreatic insulin secretion, thereof to enhance glucose uptake by PRs and other retinal cells. Additionally or alternatively, the invention relates to restoration of transduction of signaling in cone PRs by ONS induced glutamate release. The methods of the invention, in some embodiments thereof, include priming of the retina choroid and optic nerve thereof to enhance the efficacy of cell transplantation therapy. The methods of the invention, in some embodiments thereof, also include identifying a subject prone to or suffering from a disease or condition associated with reduced OBF. Methods of the invention, in some embodiments thereof, may also include monitoring the subject for prophylactic treatment where the patients are at pre-clinical stage of the disease. The OBF of subjects who had received neuromodulation treatment may also be monitored for re-treatment.The present invention, in some embodiments thereof, relates to a method and / or device for treatment of dysregulated reduced blood (e.g. reduced ocular blood flow) and, more particularly, but not exclusively, to methods and / or devices for treatment retinal, choroidal and optic nerve disorders. Optionally, treatment may include application of an effective amount of ONS ophthalmic nerve stimulation alone and / or in combination with pen-ocular administration of substance Neuropeptides / Platelet Rich Plasma (N / PRP) and / or ascorbic acid as a sympatholytic agent

The invention relates to a method for externally separated preparing retina organism sheath, wherein it comprises 1, preparing gelatin sheet that adding germ-free physiological salt water into gelatin powder, heating, boiling and fusing, cooling in cylinder module, using vibration cutter to cut it into gelation sheets; 2, storing the retina organism sheet that laying the retina adhered with choroids on the surface of gelation sheet while the choroids is upward, to be stored in storage liquid; 3, laser micro cutting the retina sheet that using quasi-molecular laser, using the optical cornea embed mode to emit laser, to cut off the choroids, then packing it with gelation, emerging it in storage liquid. The invention can separate the retina organism from choroids, with integral structure and organism activity.